The pharmaceutical research field is undergoing unprecedented transformation, with the rise of artificial intelligence (AI) emerging as a key driving force. As one of the most revolutionary technologies of the 21st century, AI is not only making its mark in drug discovery but also playing a pivotal role in the early stages of drug development thanks to its unique advantages.
Recently, AI pharmaceutical startup Chai Discovery announced the successful completion of a $30 million seed funding round, with investors including OpenAI and renowned venture firm Thrive Capital. Following this funding, Chai Discovery's valuation has reached $150 million. The funds will primarily be used to enhance the company's investment in AI and drug development technologies, expediting the new drug research process. Notably, this marks OpenAI's first investment in an AI pharmaceutical company.
From the perspective of pharmaceutical firms, Eli Lilly has also entered a collaboration agreement with Genetic Leap to develop gene therapy drugs. Lilly plans to utilize Genetic Leap’s AI platform to create oligonucleotide drugs targeting specific pathways. Under the terms of the agreement, in addition to tiered royalties, Genetic Leap could receive up to $409 million from Lilly through upfront, development, clinical, regulatory, and commercialization milestone payments. Earlier this year, Lilly partnered with OpenAI to leverage AI technology in developing antibacterial drugs, building on the success of previous pilot projects; Genetic Leap's proprietary AI platform is capable of designing RNA-targeted oligonucleotide or small molecule drugs.
Currently, there are approximately 343 AI drug development companies worldwide, with over half located in the United States. The UK and EU account for 12.5% and 13.4% of the total, while Asia represents around 12.8%, with China alone contributing about 4.7%. Additionally, the North American market dominates the global AI drug development sector, which ranks third in the Asia-Pacific region.
A Morgan Stanley report released last year indicated that the global market for AI pharmaceuticals has already reached $50 billion in the short term, with expectations for continued growth. However, while pharmaceutical companies accelerate their AI initiatives, the industry faces a dual-edged reality. Several AI pharmaceutical firms have reported layoffs and pipeline adjustments. Notably, Recursion and Exscientia finalized their merger agreement, marking the largest acquisition in the AI pharmaceutical space to date. Industry experts suggest that the merger stems from both companies lacking significant clinical data, necessitating a collaborative approach to overcome challenges.
Is AI in pharmaceuticals the future’s rising star or merely a fleeting bubble? With advances in data, algorithms, and computational power, the application of AI in healthcare is now a reality. Currently, AI technology is evolving in two major directions: first, AI-generated content (AIGC) is shifting from structured processing to specialized and interactive content creation; second, traditional AI and AIGC are expected to develop in parallel, collaborating to maximize the value of AI across various fields.
Ranking
